<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479020</url>
  </required_header>
  <id_info>
    <org_study_id>REVISAR Revision 3.2</org_study_id>
    <nct_id>NCT04479020</nct_id>
  </id_info>
  <brief_title>REcanalization of Distal Cerebral Vessels In Acute Stroke Using ApeRio®</brief_title>
  <official_title>REcanalization of Distal Cerebral Vessels In Acute Stroke Using ApeRio®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acandis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acandis GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the REVISAR PMCF is to collect data in clinical practice of the APERIO® and&#xD;
      APERIO® Hybrid(17) Thrombectomy Device, which are intended to restore blood flow in the&#xD;
      neurovasculature by removing thrombus in patients experiencing ischemic stroke.&#xD;
      Recanalization status will be assessed at the end of the procedure using the modified TICI&#xD;
      (Thrombolysis in cerebral infarction) score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: prospective, multicenter, single-arm, open-label Participants: 10 participating&#xD;
      centers in Germany planned PI: Dr. Franziska Dorn, University Hospital Bonn, Germany&#xD;
      Estimated Enrolment: A minimum of 130 patients treated with the APERIO® or APERIO® Hybrid(17)&#xD;
      Thrombectomy Device due to thrombotic occlusions in a distal vessel of the anterior and&#xD;
      posterior circulation (postbifurcal MCA, ACA, PCA)&#xD;
&#xD;
      Follow up: 3 months Estimated Final Assessment: End of 2022&#xD;
&#xD;
      This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical&#xD;
      Follow-up Study to collect comprehensive information on technical and clinical success and&#xD;
      safety of the use of APERIO® and APERIO® Hybrid(17) Thrombectomy Device inin a distal vessel&#xD;
      of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA). Aperio® and Aperio®&#xD;
      Hybrid(17) Thrombectomy Device will be used within its approved indication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Primary efficacy endpoint</measure>
    <time_frame>Immediatley after interventional procedure</time_frame>
    <description>Successful arterial recanalization of occluded target vessel measured by mTICI score of 2b or 3 following the use of the APERIO® and APERIO® Hybrid(17) Thrombectomy Device without any symptomatic intracranial hemorrhage and rescue therapy within 3 passes per Device mTICI describes the response of thrombolytic therapy in ischemic stroke. Higashida et al. 2003: Grade 0: no perfusion Grade 1: penetration with minimal perfusion Grade 2: partial perfusion Grade 2A: only partial filling (less than two-thirds) of the entire vascular territory is visualized Grade 2B: complete filling of all of the expected vascular territory is visualized but the filling is slower than normal Grade 3: complete perfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>48 hours</time_frame>
    <description>• Symptomatic intracranial hemorrhage (sICH): ICH in periprocedural (&lt;48 hours) CT associated with worsening of NIHSS by ≥ 4 points within 48 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>90 days</time_frame>
    <description>Rates of device and procedure related (serious) adverse events ((S)AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety endpoint</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Good neurological outcome</measure>
    <time_frame>90 days</time_frame>
    <description>mRS (modified Ranking Scale)= 0-2&#xD;
0 No Symptoms&#xD;
No significant disability, despite symptoms, able to perform all usual duties and activities&#xD;
Slight disability; unable to perform all previous activities but able to look after own affairs without assistance&#xD;
Moderate disability; requires some help, but able to walk without assistance&#xD;
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance&#xD;
Severe disability bedridden incontinent and requires constant nursing care and attention&#xD;
Patient died</description>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Acute Stroke</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mechanical Thrombectomy</intervention_name>
    <description>Mechanical thrombectomy requiring the use an APERIO® or APERIO® Hybrid(17) Thrombectomy device due to an thrombotic occlusion in a distal vessel of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with an APERIO® or APERIO® Hybrid(17) Thrombectomy Device due to a&#xD;
        thrombotic occlusion in distal vessel of the anterior and posterior circulation&#xD;
        (postbifurcal MCA, ACA, PCA).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient treated with the APERIO® or APERIO® Hybrid(17) Thrombectomy Device due to&#xD;
             occlusion in distal vessel of the anterior and posterior circulation (postbifurcal&#xD;
             MCA, ACA, PCA) according to IFU&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pre stroke mRS ≥ 3&#xD;
&#xD;
          -  Any contraindication according to IFU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franziska Dorn, Prof. Dr. med.</last_name>
    <phone>+49 (0) 228-287-16505</phone>
    <email>Franziska.Dorn@ukbonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Schlosspark Klinik Charlottenburg</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Förschler, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Dorn, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Turowski, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kallenberg Kai, PD. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marielle Ernst, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Kabbasch, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A. ö. R.</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Behme, PD. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borggrefe Jan, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Liebig, Prof.Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>radprax Neurozentrum Solingen</name>
      <address>
        <city>Solingen</city>
        <zip>42697</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Nordmeyer, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

